Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Roy S. Herbst et al.|Clinical Cancer Research|2024Cited by 42
Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum DiscussionRajeshwari Sridhara, Cindy Lu, Olga Marchenko et al.|Statistics in Biopharmaceutical Research|2021Cited by 35
Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum DiscussionRajeshwari Sridhara, Bruce Binkowitz, Olga Marchenko et al.|Statistics in Biopharmaceutical Research|2021Cited by 12
Supplementary Figure 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Unknown|2024Cited by 0
Supplementary Table 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Unknown|2024Cited by 0